156 related articles for article (PubMed ID: 38494279)
1. Paraneoplastic movement disorders.
McKeon A; Tracy J
Handb Clin Neurol; 2024; 200():211-227. PubMed ID: 38494279
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune movement disorders.
Mckeon A; Vincent A
Handb Clin Neurol; 2016; 133():301-15. PubMed ID: 27112684
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune Movement Disorders: a Clinical and Laboratory Approach.
Honorat JA; McKeon A
Curr Neurol Neurosci Rep; 2017 Jan; 17(1):4. PubMed ID: 28120141
[TBL] [Abstract][Full Text] [Related]
4. Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
Jones AL; Flanagan EP; Pittock SJ; Mandrekar JN; Eggers SD; Ahlskog JE; McKeon A
JAMA Neurol; 2015 Nov; 72(11):1304-12. PubMed ID: 26414229
[TBL] [Abstract][Full Text] [Related]
5. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
Levite M
J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
[TBL] [Abstract][Full Text] [Related]
6. Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients.
Iorio R; Damato V; Evoli A; Gessi M; Gaudino S; Di Lazzaro V; Spagni G; Sluijs JA; Hol EM
J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):138-146. PubMed ID: 28951498
[TBL] [Abstract][Full Text] [Related]
7. Update in Autoimmune Movement Disorders: Newly Described Antigen Targets in Autoimmune and Paraneoplastic Cerebellar Ataxia.
Garza M; Piquet AL
Front Neurol; 2021; 12():683048. PubMed ID: 34489848
[TBL] [Abstract][Full Text] [Related]
8. The Discovery of Anti-Yo (Anti-PCA1) Antibody in Patients with Paraneoplastic Cerebellar Degeneration: Opening a Window into Autoimmune Neurological Disease.
Greenlee JE; Brashear HR
Cerebellum; 2023 Aug; 22(4):531-533. PubMed ID: 35881322
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune and paraneoplastic movement disorders: An update.
Baizabal-Carvallo JF; Jankovic J
J Neurol Sci; 2018 Feb; 385():175-184. PubMed ID: 29406902
[TBL] [Abstract][Full Text] [Related]
10. [A case of human immunodeficiency virus infection with cerebellar ataxia that suggested by an association with autoimmunity].
Nagao S; Kondo T; Nakamura T; Nakagawa T; Matsumoto S
Rinsho Shinkeigaku; 2016 Apr; 56(4):255-9. PubMed ID: 27010096
[TBL] [Abstract][Full Text] [Related]
11. Inositol 1,4,5-trisphosphate receptor type 1 autoantibody (ITPR1-IgG/anti-Sj)-associated autoimmune cerebellar ataxia, encephalitis and peripheral neuropathy: review of the literature.
Jarius S; Bräuninger S; Chung HY; Geis C; Haas J; Komorowski L; Wildemann B; Roth C
J Neuroinflammation; 2022 Jul; 19(1):196. PubMed ID: 35907972
[TBL] [Abstract][Full Text] [Related]
12. Movement disorders in paraneoplastic and autoimmune disease.
Panzer J; Dalmau J
Curr Opin Neurol; 2011 Aug; 24(4):346-53. PubMed ID: 21577108
[TBL] [Abstract][Full Text] [Related]
13. Paraneoplastic movement disorders: phenomenology, diagnosis, and treatment.
Chirra M; Marsili L; Gallerini S; Keeling EG; Marconi R; Colosimo C
Eur J Intern Med; 2019 Sep; 67():14-23. PubMed ID: 31200996
[TBL] [Abstract][Full Text] [Related]
14. Paraneoplastic movement disorders.
Grant R; Graus F
Mov Disord; 2009 Sep; 24(12):1715-24. PubMed ID: 19562765
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia.
Damato V; Papi C; Spagni G; Evoli A; Silvestri G; Masi G; Sabatelli E; Campetella L; McKeon A; Andreetta F; Riso V; Monte G; Luigetti M; Primiano G; Calabresi P; Iorio R
Eur J Neurol; 2022 Feb; 29(2):564-572. PubMed ID: 34710286
[TBL] [Abstract][Full Text] [Related]
16. Paraneoplastic autoimmune movement disorders.
Lim TT
Parkinsonism Relat Disord; 2017 Nov; 44():106-109. PubMed ID: 29097081
[TBL] [Abstract][Full Text] [Related]
17. Paraneoplastic movement disorders.
Mehta SH; Morgan JC; Sethi KD
Curr Neurol Neurosci Rep; 2009 Jul; 9(4):285-91. PubMed ID: 19515280
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune movement disorders with neuronal antibodies - an update.
Balint B; Bhatia KP
Curr Opin Neurol; 2021 Aug; 34(4):565-571. PubMed ID: 34010219
[TBL] [Abstract][Full Text] [Related]
19. CDR2 and CDR2L line blot performance in PCA-1/anti-Yo paraneoplastic autoimmunity.
Vorasoot N; Scharf M; Miske R; Thakolwiboon S; Dubey D; Mills JR; Pittock SJ; Zekeridou A; Ott A; McKeon A
Front Immunol; 2023; 14():1265797. PubMed ID: 37841252
[TBL] [Abstract][Full Text] [Related]
20. Anti-Ri-associated paraneoplastic ophthalmoplegia-ataxia syndrome in a woman with breast cancer: a case report and review of the literature.
Sena G; Gallo G; Vescio G; Gambardella D; de Franciscis S; Renne M
J Med Case Rep; 2020 Jun; 14(1):67. PubMed ID: 32527295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
